Lawrence Steinman

Publication Details

  • PREVENTION OF EXPERIMENTAL ENCEPHALOMYELITIS WITH PEPTIDES THAT BLOCK INTERACTION OF T-CELLS WITH MAJOR HISTOCOMPATIBILITY COMPLEX PROTEINS PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Sakai, K., Zamvil, S. S., Mitchell, D. J., Hodgkinson, S., Rothbard, J. B., Steinman, L. 1989; 86 (23): 9470-9474

    Abstract:

    Two synthetic immunodominant and nonencephalitogenic peptides of myelin basic protein, N1-20 and AcN9-20, effectively compete with an encephalitogenic peptide, AcN1-11, in an in vitro T-cell response restricted by class II major histocompatibility complex products (I-Au). These mutant peptide constructs, which do not occur in nature, also compete with the self-antigen for the in vivo induction of T cells primed with the encephalitogen AcN1-11. By using these nonpathogenic competitor peptides, it is possible to prevent the development of a prototypic T-cell-mediated autoimmune disease, experimental allergic encephalomyelitis. These results suggest possibilities for the utilization of competitor peptides for therapy of T-cell-mediated autoimmune diseases linked to specific major histocompatibility complex genes.

    View details for Web of Science ID A1989CC53300084

    View details for PubMedID 2480602

Stanford Medicine Resources:

Footer Links: